New combo targets breast cancers that slip past standard treatments
NCT ID NCT05633979
First seen Jan 22, 2026 · Last updated Jun 12, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug (valemetostat) combined with a standard targeted therapy (trastuzumab deruxtecan) in people with metastatic breast cancer that has low, ultra-low, or no HER2 protein. The goal is to find a safe dose and see if the combination shrinks tumors. About 17 adults with this specific breast cancer type will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.